WO2004030680A1

WO2004030680A1 - Pharmaceutical composition comprising bando deep ocean water of the concentrate thereof for treatment and prevention of liver disease

Info

Publication number: WO2004030680A1
Application number: PCT/KR2003/002016
Authority: WO
Inventors: Ja Lim; G-Rewo Lim
Original assignee: Individual
Current assignee: Individual
Priority date: 2002-10-01
Filing date: 2003-09-30
Publication date: 2004-04-15
Anticipated expiration: 2005-04-01
Also published as: AU2003265107A1; KR20040030360A

Abstract

A pharmaceutical composition and health care food comprising Bando Deep Ocean Water', as used herein, means deep ocean like water drawn up from the underground at the depth ranging from 700 to 1000 m near Korean seashore region, contain not only inorganic component such as Na, Ca, Mg and K but also metal ion such as Se and Zn and have potent hepato-protective activity, which can be useful to treat or prevent liver disease such as hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer.

Description

PHARMACEUTICAL COMPOSITION COMPRISING BANDO DEEP OCEAN WATER OF THE CONCENTRATE THEREOF FOR TREATMENT AND PREVENTION OF LIVER DISEASE

BACKGROUND OF THE INVENTION

Technical Field

The present invention relates to a pharmaceutical composition containing Bando Deep Ocean Water or the concentrate thereof for treatment and prevention of liver disease.

Background Art

Hepatitis afflicts increasing numbers of population, and due to the lack of therapeutically effective drugs, it usually progresses to chronic hepatitis, liver cirrhosis or cancer. Various types of hepatitis may be developed when a patient is exposed to, e.g., stress, excessive consumption of alcohol, and/or hepatotoxic substances.

It has been known that the main metabolism of alcohol is the transformation of alcohol into acetaldehyde by way of several enzymes existing in liver such as alcohol dehydrogenase, microsomal ethanol-oxidizing system (MEOS) and catalase enzyme etc (K. Ebihara et al, Agri. Biol. Chem., 52, pl311, 1988).

There has been lots of studies to develop effective drug or health food to treat or prevent liver disease such as ursodeoxycholic acid, chenodeoxycholic acid and the like (Japanese Patent Publication No. 1992-235918).

Deep ocean water is located at below 200m from sea surface where does not occur photosynthesis and therefore, it has lots of characteristics such as abundant inorganic mineral such as Zn, Se, Mn other than essential minerals i.e., Mg, Ca, K, Na, which can endow human or animal body with immune enhancing activity; high purity without contamination with various external polluting factors, for example, air, chemicals, pathogenic bacteria and so on; matoing activity by dint of abundant enzymes; physical stability; and radical scavenging activity etc (Japanese Patent No. 1995-34728).

Therefore, there have been lots of reports on the development of deep ocean water due to above-described favorable advantages till now. For example, Japanese Patent Publication No. 2001-198575 discloses alkali reduction water reported to have treating activity of various gastrointestinal diseases such as intestinal abnormal fermentation, chronic diarrhea, indigestion, hyperchylia, etc, and strong acidic oxidization water reported to be used as a disinfectant of medical devices and food due its bactericidal activity.

Japanese Patent Publication No. 2580428 discloses health beverage for the prevention of various present human disease such as diabetes, allergic disease, and cardiac infarction.

Japanese Patent Publication No. 1993-219921 and 1985-255729 disclose nutrient water comprising desalted deep ocean water and vitamins and health mineral water beverage respectively, all of which are incorporated herein by reference.

However, above described references relate to deep ocean water drawn up from the Fujiyama Bay in Japan and there have been no suggestion or disclosure on specific medical use and Deep Ocean like water drawn up from the seashore region.

Accordingly, present inventors endeavored to investigate specific pharmacological activity of deep ocean like water drawn up from the seashore region designated as Bando Deep Ocean Water (BDW) herein, found that it has potent hepato-protective activity by experimenting in vitro test and clinical test and finally have accomplished present invention.

SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a pharmaceutical composition for prevention and treatment of liver disease, comprising Bando Deep Ocean Water and a pharmaceutically acceptable carrier.

Disclosure of the invention

In accordance with one aspect of the present invention, there is provided a pharmaceutical composition for prevention and treatment of liver disease, comprising Bando Deep Ocean Water, hereinafter call as BDW, and a pharmaceutically acceptable carrier.

The term "Bando Deep Ocean Water", as used herein, means deep ocean like water drawn up from the underground at the depth ranging from 700 to 1000 m near Korean seashore region, preferably, East seashore region, more preferably, Kyonggi province region and comprise all the types such as natural form itself containing salt ingredient (BDW-1) and the concentrate thereof (BDW-2) and desalted form without salt ingredient (BDW-3) and the concentrate thereof (BDW-4), all of which are characterized in containing not only inorganic component such as Na, Ca, Mg and K but also metal ion such as Se and Zn. Above described liver diseases comprise hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer.

Above described various forms of BDW may be prepared by the following procedures, which are merely exemplary and in no way limit the invention.

For example, BDW-1 drawn up from the underground at the depth ranging from 700 to 1000 m near Korean seashore region is subject to at least one desalting step selected from ion exchange column chromatography, the evaporative concentration process comprising natural evaporation process in the shadow, heat treatment and filtration process to remove resulting crude salt or electrolysis method resolving salt into ions through electrolyte apparatus to obtain BDW-3 and subsequent drying step adopting in conventional manner such as natural seasoning, hot wind drying, lyophilization and the like to obtain BDW-2 and BDW-4.

Specifically, in carrying out above described ion exchange, either a cation exchange resin or an anion exchange resin may be used. Examples of exchange resins that can be used for this purpose are: strong acidic cation exchange resins such as AG 50W-x8, Amberlite IR- 120, and Dowex 50W-x8; weak acidic cation exchange resins such as Amberlite IRC-50, Bio- Rex 70, Duolite-436; weak basic cation exchange resins such as Amberlite IRA-67, and Dowex 3-x4A; strong basic cation exchange resins such as AG 2x8, Amberlite IRA-400, and Dowex 2- x8; modified cellulose cation exchange resins such as CM-Celluose and SE-Cellulose; and anion exchange resins such as DEAE Celluose; cationic sephadex-type resins such as G-25 and G-50 bead type cross-linked dextran resins; and modified bead-type ion exchange resins made from agarose such as Cepharose CL, Biogel A Cepharose resin, Fractogels and Toyopearl. The preferred resins are Toyopearl DEAE type exchange resins, and the more preferred are Toyoprearl DEAE-650C type exchange resins. In carrying out above described electrolysis, electrolysis apparatus is not limited which can resolve water into ions, for example, two-part electrolytic cell type divided with diaphram. There are several types according to water supply methods preferably, once water supply to reservoir to be resolved for certain period, subsequent water supply to reservoir through tap water, h above described electrolysis, ferrite electrode, platinum plating titan electrode, titan platinum plasticized electrode and the like are preferable as an anode and stainless electrode, platinum plating titan electrode, titan platinum plasticized electrode and the like are preferable as a cathode.

BDW-1, 2, 3 and 4 prepared by above preparation method contain abundant mineral ingredient.

Various experiments clearly show that BDW possess a high antihepatotoxicity and are effective for preventing and treating liver diseases.

Thus, the BDW of the present invention may be employed as a pharmaceutical agent for preventing or treating liver toxicity and liver diseases such as hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer.

In accordance with another aspect of the present invention, there is also provided an use of BDW for manufacture of medicines employed for treating or preventing various liver disease comprising hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer in men or mammals.

In accordance with another aspect of the present invention, there is also provided an method of treating or preventing various liver disease comprising hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer in human or mammals, wherein the method comprises administering a therapeutically effective amount of BDW.

The pharmaceutical composition of the present invention comprises above BDW as 0.01 to 80 %, preferably 1 to 50 % by weight based on the total weight of the composition.

Hereinafter, the following formulation methods and excipients are merely exemplary and in no way limit the invention.

The inventive pharmaceutical formulation may be prepared in accordance with any of the conventional procedures, hi preparing the formulation, the active ingredient is preferably admixed or diluted with a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet or other container. When the carrier serves as a diluent, it may be a solid, semi- solid or liquid material acting as a vehicle, excipient or medium for the active ingredient. Thus, the formulation may be in the form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, sterile packaged powder and the like.

Examples of suitable carriers, excipients, or diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoates, propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulation may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The composition of the invention may be formulated so as to provide a quick, sustained or delayed release of the active ingredient after it is administrated to a patient, by employing any one of the procedures well known in the art.

The pharmaceutical formulation of the present invention can be administered via various routes including oral, transdermal, and subcutaneous, intravenous and intramuscular introduction. For treating a human patient, a typical daily dose of the above-mentioned compound may range from about 0.01 to 10 g/kg body weight, preferably 1 to 5 g/kg body weight, and can be administered in a single dose or in divided doses. However, it should be understood that the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the condition to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.

It is still another object of the present invention to provide a health care food or food additives comprising above BDW, together with a sitologically acceptable additive for prevention and improvement of liver disease comprising hangover and hepatitis.

The above-mentioned BDW can be added to food or beverage for preventing and alleviation of various liver diseases and hangover. The amount of said BDW that may be added to food or beverage for the purpose of preventing liver diseases may generally range from about

0.1 to 15 w/w %, preferably 1 to 10 w/w % based on the total weight of food, and 1 to 30 g, preferably 3 to 10 g based on 100 mi of beverage.

The health care beverage composition of the present invention may contain other components, e.g., deodorants and natural carbohydrates as in conventional beverages. Examples of such natural carbohydrates are monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; conventional sugars such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol and erythritol. As the deodorant, a natural deodorant such as taumatin, levaudioside A, and glycyrrhizin, or a synthetic deodorant such as saccharin and aspartam may be used. The amount of the above-described natural carbohydrate is generally in the range of about 1 to 20g, preferably 5 to 12 g based on 100ml of beverage.

Other components that may be added to the inventive food or beverage composition are various nutrients, vitamins, minerals, synthetic flavoring agents, coloring agents pectic acid and its salt, alginic acid and its salt, organic acids, protective colloidal adhesives, pH controlling agents, stabilizers, preservatives, glycerin, alcohol, carbonizing agents, fruit juices and vegetable juices.

Brief Description of the Drawings

The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, which respectively show:

Fig. 1 shows changes of GOT and GPT value according to increased concentration of drug.

Best Mode for Carrying Out the Invention

The following Examples, Experimental Examples and Formulation Examples are intended to further illustrate the present invention without limiting its scope.

Example 1 : Preparation method of BDW-1 and 2

20 kg of Bando Deep Ocean Water was drawn up from the underground at the depth at 800 m located at Dukwoo-ri, Paltan-myeon, Hwasung-si, Kyonggi Province, South Korea and designated as BDW-1 herein. 2 kg of BDW-1 was used as test sample and remaining 18 kg of BDW-1 was lyophilized with freeze dryer (SamwonNangyul SFDSM24L model, Korea) to obtain 150 mg of concentrated powder designated as BDW-2, which was used as test sample.

Example 2: Preparation method of BDW- 3

20 kg of BDW-1 was poured into water supply reservoir divided with cathode and anode parts of two-part reservoir type electrolysis apparatus and electrolysis was performed by flowing 0.1 to 3.0A of direct current for 60 mins to obtain 8 kg of desalted BDW solution designated as BDW-3, which was used as test sample.

Example 3: Preparation method of BDW- 4 (1)

20 kg of BDW-1 was poured into water supply reservoir divided with cathode and anode parts of two-part reservoir type electrolysis apparatus and electrolysis was performed by flowing 0.1 to 3.0A of direct current for 60 mins to obtain 8 kg of desalted BDW solution designated as BDW-3. And then the solution was heated at the temperature ranging 80 to 120 °C for 24 hrs and dried at room temperature to obtain 200 mg of desalted BDW powder designated as BDW-4, which was used as test sample.

Example 4: Preparation method of BDW- 4 (2)

20 kg of BDW-1 was poured into 160 i of Toyo pearl® DEAE-650C ion exchange resin (4.0x 30cm, Tosoh Co. Japan) equilibrated with desalted distilled water and eluted successively with 0, 0.1, 0.2, 0.3 and 3M NaCl solutions with a eluting velocity of 2 mMir. The eluted solutions were dialyzed using a dialysis membrane (Sigma co. USA) having 32 mm of mean width and 100 mMeet volume of benzoylated dialysis tubing ninning with desalted water three times for 4 hrs. The filtrates was lyophilized with freeze dryer (SamwonNangyul SFDSM24L model, Korea) to obtain 150 mg of concentrated powder designated as BDW-4, which was used as test sample.

Example 5: Characterization and component analysis of BDW

Comparison with the characters of BDW and Japanese Deep Ocean Water

Table 1 shows distinct characteristics of BDW comparing with conventional Deep Ocean Water obtained in Japan and disclosed in Korean Patent Publication No 2002-4598.

As can be seen in Table 1, BDW has fundamentally different characteristic from conventional Japanese Deep Ocean Water in the aspect of Existing depth, mean temperature, degree of hardness and Mean pH.

Table 1. Characteristic of BDW and Japanese Deep Ocean Water

Elementary Analysis of BDW-1

To determine the consisting component of BDW-1 and Deep Ocean Water (Japan), the elementary analysis of BDW-1 and Deep Ocean Water (Japan) was performed at KTRICI (Korea Testing and Research Institute for Chemical Industry) located at Seoul in Korea by conventional analysis method disclosed in APHA (revised Ed, 1998) and the result thus obtained is shown in Table 2.

Table 2. Result of Elemental analysis

As can be seen in Table 2, the amount of several minerals such as Fe, Mn, Zn etc in BDW-1 was much more abundant ranging 10 to 10000 fold than those of Deep Ocean Water

(Japan) and particularly, The amount of Ca ion in BDW-1 was more abundant than that of

Mg differing with Deep Ocean Water (Japan), which shows the consisting ingredients in

BDW-1 are fundamentally different with those of Deep Ocean Water (Japan).

Experimental Example 1 : Hepatoprotective activity of BDW

To confirm the hepatoprotective activity of BDW-1, the inhibition of liver toxicity induced by alcohol administration was investigated by determining blood GOT and GPT values in rat as follows:

(1) Preparation of experimental animal

Male Sprague-Dawley rats weighing 150 to 250g were acclimated in environmental for 3 days and starved for 6 hours.

25 numbers of rats were divided into five groups consisting of each 5 rates, i.e., normal control group as a negative control, alcohol treatment group as a positive control, 0.17, 0.50 and 1.50 g/kg of BDW-2 prepared in BDW-4 administration group as test samples. (2) Preparation of test samples

To normal control group, 1 ml of saline solution was aciministrated and 1 hour after, 7.6mg/kg of saline solution was again administrated. To alcohol administration group, 1 ml of saline solution was adirώiistrated and 1 hour after, 7.6mg/kg (6g/kg) of alcohol was again administrated. To test sample group, 0.17, 0.50 and 1.50 g/kg of BDW-4 prepared in BDW-4 were administrated according to ach dosage and 1 hour after, 7.6mg/kg of alcohol was again orally administrated.

(3) Autopsy and blood samples After the administration of alcohol, the rats were anatomized 12 hours later and blood samples were harvested from mouse leg vein. The samples were centrifuged at the speed of 3000 rpm for 10 minutes to isolate supernatant serum.

(4) Determination of GOT and GPT GOT substrate solution was adjusted to 1 ml and incubated with water bath at 37 ^°C for 3 minutes. Each 0.2 ml of testing serum was added thereto and further incubated with water bath at 37 ^°C for 60 minutes. 1 ml of GOT staining solution was added thereto and left alone at room temperature for 20 minutes. 10 ml of 0.4 N NaOH was added to quench the reaction and sufficiently mixed. The resulting color of solution was determined by GOT kit apparatus (Yeoungdong Pharm. Co.) at 505nm.

GPT substrate solution was adjusted to 1 ml and incubated with water bath at 37 ^°C for 3 minutes. Each 0.2 ml of testing serum was added thereto and further incubated with water bath at 37 ^°C for 60 minutes. 1 ml of GPT staining solution was added thereto and left alone at room temperature for 20 minutes. 10 ml of 0.4 N NaOH was added to quench the reaction and sufficiently mixed. The resulting color of solution was determined by GPT kit apparatus (Yeoungdong Pharm. Co.) at 505nm.

5 Test Result of GOT & GPT

As can be seen in Table 3, while negative control group showed normal range of GOT (39.0+0.0) and GPT (10.0+0.0) value and positive control showed about three times value of GOT (114.3+13.7) and about two times value of GPT (26.2+6.63), which are statistically significant value (GOT: pO.OOl; GPT: 0.17 g kg pO.Ol, 0.5 g/kg & 1.5 g/kg pO.OOl), BDW administration group showed decreased values of GOT and GPT in dose dependent manner, in particular, GPT value of 1.5 g/kg administration group was reduced to normal value, which is confirmed that BDW effectively inhibit the expression of hepato- toxicity induced by alcohol. Table 3. Result of GOT & GPT test

Experimental Example 2: Clinical Example

Clinical Example 1 :

60 years old Korean man lived at Boryung city in Korea, had complained about hangover caused by overdrinking alcohol. He had been used to take several conventional health drinks for alleviating hangover, however, was not satisfied with their efficacy. 150 ml of BDW-3 had been prescribed twice a day orally for three months from Jan. 1 to April, 1 2003, and does not suffer from hangover not any more.

Clinical Example 2:

29 years old Korean man lived at Seoul city in Korea, had complained about hangover caused by overdrinking. While the blood alcohol concentration determined by breath alcohol tester (AL-3000, Sentech Korea Co.) was 0.1 at 10 minutes later after 230 ml of Soju liquor (22% alcohol, Korea) was taken orally, the blood alcohol concentration was significantly reduced to 0.06 at 10 minutes and to 0.01 at 1 hour after 200 ml of BDW-1 was taken orally.

Clinical Example 3:

40 years old Korean female lived at Seoul in Korea, had been treated with Zepix (Glaxo SmithKline Co. Ltd.) at a dose of lOOmg per day for 30 months from Jul. 1, 1999 to Dec. 1, 2002 and her GOT (5,500 KU) and GPT (190,000 KU) value was very high at that time. However, after BDW-4 was prescribed an oral dosage regimen of 1000 mg/day twice a day for 2 months from Jan., 1, 2003 to Mar. 5, 2003, her GOT (5,500 KU) and GPT (190,000 KU) value was significantly decreased to the GOT value (43.42 %) and GPT value (31.37 %) and the values of WBC, RBC, HB and HT identified through CBC (complete blood cell count) diagnosis, were maintained within each normal range, which indicates no toxicity and adverse effect of BDW-4.

The BDW of the present invention can be used in preparing a pharmaceutically effective powder, tablet, capsule, injection or liquid composition according to any one of the known conventional methods, as exemplified below.

Experimental Example 3: Toxicity test

Methods The acute toxicity tests on ICR mice (mean body weight 25+5g) and Sprague-

Dawley rats (235+ lOg) were performed using the BDW-2 and 4. Each group consisting of 3 mice or rats was administrated intraperitoneally with 20mg/kg, lOmg/kg and lmg/kg of test compounds or solvents (0.2 ml, i.p.), respectively and observed for 24 hrs.

Results

There were no treatment-related effects on mortality, clinical signs, body weight changes and gross findings in any group or either gender. These results suggested that the compounds prepared in the present invention were potent and safe.

Hereinafter, the formulating methods and kinds of excipients will be described, but the present invention is not limited to them. The representative preparation examples were described as follows.

Preparation of powder BDW-2 500mg

Corn Starch lOOmg

Lactose lOOmg

Talc lOmg Powder preparation was prepared by mixing above components and filling sealed package. Preparation of tablet

BDW-2 lOOmg

Corn Starch lOOmg

Lactose lOOmg Magnesium Stearate 2mg

Tablet preparation was prepared by mixing above components and entabletting.

Preparation of capsule

BDW-2 50mg Lactose 50mg

Magnesium Stearate lmg

Tablet preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method.

Preparation of injection

BDW-2 lOOmg

Distilled water for inj ection optimum amount pH controller optimum amount

Dissolving active component, controlling pH to about 7.5 and then filhng all the components in 2 ml ample and sterilizing by conventional injection preparation method prepared injection preparation.

The heath care food was exemplarily prepared by the following method.

[Preparation of health care food]

A scorched dried meal mixture of brown rice, barley, glutinous rice and Job's tear was pulverized and sieved to obtain grain particles of 60 meshes or less. Also, a mixture of black bean, black sesame and wild sesame was steamed, dried, scorched, pulverized and sieved to obtain seed particles of 60 mesh or less. The dried BDW-2 obtained in Example 1 was pulverized and sieved to obtain particles of 60 meshes or less, which were mixed with the grain particles and seed particles in the following proportions to prepare a granule type health food.

Grains : brown rice 30w%, Job's tear 15w%, barley 20w%, Seeds : wild sesame 7w%, black bean 8w%, black sesame 7w%,

Dried powder of BDW : 3w%, Shiitake mushroom 0.5w%, rehmania root 0.5w% The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims

Industrial Applicability

The compounds according to the present invention are useful in the prevention, or treatment of various liver diseases including hangover, hepatitis, hepatic cirrhosis and liver cancer by reducing blood GOT and GPT value.

Claims

1. A pharmaceutical composition for prevention and treatment of liver disease, comprising Bando Deep Ocean Water, designated as BDW, and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 wherein BDW is selected from natural form itself containing salt ingredient (BDW-1) and the concentrate thereof (BDW-2), desalted form without salt ingredient (BDW-3) and the concentrate thereof (BDW-4).

3. The pharmaceutical composition of claim 1 wherein BDW is drawn up from the underground at the depth ranging from 700 to 1000 m near Korean seashore region.

4. The pharmaceutical composition of claim 3 wherein BDW is drawn up from the underground at the depth ranging from 700 to 1000 m near East seashore region.

5. The pharmaceutical composition of claim 4 wherein BDW is drawn up from the underground at the depth ranging from 700 to 1000 m near Kyonggi province region.

6. The pharmaceutical composition of claim 1 wherein BDW is characterized in containing not only inorganic component such as Na, Ca, Mg and K but also metal ion such as

Se and Zn

7. The pharmaceutical composition of claim 1 wherein liver diseases comprise hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer.

8. The pharmaceutical composition of claim 1 of which type is selected from tablet, capsule, solution, suspension or syrup.

9. The pharmaceutical composition of claim 1 wherein the amount of said BDW ranges from 0.01 to 50 % by weight based on the total weight of the composition.

10. A use of BDW as set forth in claim 1 for manufacture of medicines employed for treating or preventing various liver disease comprising hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer in human or mammals.

11. A method of treating or preventing various liver disease comprising hangover, fatty liver, chronic or acute hepatitis, hepatocirrhosis and liver cancer in men or mammals, wherein the method comprises administering a therapeutically effective amount of BDW as set forth in claim 1.

12. A health care food comprising Bando Deep Ocean Water as set forth in claim 1, and a sitologically acceptable additive for the prevention and alleviation of liver disease comprising hangover and hepatitis.

13. The health care food of claim 12, wherein the food is of a powder, tablet, capsule, or beverage type.